Shares of China Biologic Products Inc. (NASDAQ:CBPO) dropped 2.2% on Friday . The company traded as low as $118.67 and last traded at $118.91, with a volume of 81,659 shares changing hands. The stock had previously closed at $121.60.

CBPO has been the subject of a number of research reports. Jefferies Group restated a “buy” rating on shares of China Biologic Products in a research note on Saturday, June 4th. Zacks Investment Research lowered China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. Finally, Credit Suisse Group AG upgraded China Biologic Products from a “neutral” rating to an “outperform” rating in a research report on Tuesday, July 5th.

The stock has a market capitalization of $3.17 billion and a PE ratio of 35.71. The company has a 50 day moving average price of $110.63 and a 200 day moving average price of $115.63.

China Biologic Products (NASDAQ:CBPO) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. The company had revenue of $85.60 million for the quarter, compared to the consensus estimate of $74 million. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. Equities research analysts anticipate that China Biologic Products Inc. will post $4.29 EPS for the current year.

In other news, VP Ming Yin sold 19,618 shares of the company’s stock in a transaction on Friday, May 20th. The stock was sold at an average price of $113.64, for a total transaction of $2,229,389.52. Following the completion of the sale, the vice president now directly owns 51,419 shares in the company, valued at approximately $5,843,255.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Wp X. Biologics Llc sold 2,775,000 shares of the company’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total value of $308,025,000.00. The disclosure for this sale can be found here.

Other hedge funds have made changes to their positions in the company. Russell Frank Co increased its stake in shares of China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock valued at $1,993,000 after buying an additional 5,764 shares in the last quarter. Employees Retirement System of Texas acquired a new stake in shares of China Biologic Products during the fourth quarter valued at $2,846,000. Finally, WCM Investment Management CA increased its stake in shares of China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock valued at $8,655,000 after buying an additional 11,282 shares in the last quarter.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.